The current theory of the prostate cancer stem cell (PCSC) may help us understand cancer recurrence and treatment failure of prostate cancer, and CD133 is one of the most powerful biomarkers to identify and isolate PCSCs. This evidence concerns the gene PROM1 and prostate carcinoma.